Antacid exposure and immunotherapy outcomes among patients with advanced hepatocellular carcinoma
Background: Antibiotic exposure has been associated with worse outcomes with immune checkpoint inhibitors (ICIs) in cancer patients, likely due to disruption of the gut microbiome. Other commonly prescribed medications, such as proton pump inhibitors (PPIs) and histamine-2-receptor antagonists (H2RA...
Main Authors: | Tomi Jun, Umut Ozbek, Sirish Dharmapuri, Camille Hardy-Abeloos, Huili Zhu, Jung-Yi Lin, Nicola Personeni, Tiziana Pressiani, Naoshi Nishida, Pei-Chang Lee, Chieh-Ju Lee, Hannah Hildebrand, Neil Nimkar, Sonal Paul, Petros Fessas, Muntaha Naeem, Dominik Bettinger, Uqba Khan, Anwaar Saeed, Yi-Hsiang Huang, Masatoshi Kudo, Lorenza Rimassa, Thomas U. Marron, David J. Pinato, Celina Ang |
---|---|
Format: | Article |
Language: | English |
Published: |
SAGE Publishing
2021-04-01
|
Series: | Therapeutic Advances in Medical Oncology |
Online Access: | https://doi.org/10.1177/17588359211010937 |
Similar Items
-
Post-registration experience of nivolumab in advanced hepatocellular carcinoma: an international study
by: Dominik Bettinger, et al.
Published: (2020-10-01) -
Impact of corticosteroid therapy on the outcomes of hepatocellular carcinoma treated with immune checkpoint inhibitor therapy
by: Dominik Bettinger, et al.
Published: (2020-10-01) -
Patterns and outcomes of subsequent therapy after immune checkpoint inhibitor discontinuation in HCC
by: Rohini Sharma, et al.
Published: (2022-07-01) -
Early Antibiotic Exposure Is Not Detrimental to Therapeutic Effect from Immunotherapy in Hepatocellular Carcinoma
by: Petros Fessas, et al.
Published: (2021-10-01) -
Which choice of therapy when many are available? Current systemic therapies for advanced hepatocellular carcinoma
by: Nicola Personeni, et al.
Published: (2020-03-01)